Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity

Journal of Experimental Medicine

Volumn 214, Issue 4, 2017, Pages 1081-1092

  Czirr, Eva ^a,f   Castello, Nicholas A ^c   Mosher, Kira I ^a   Castellano, Joseph M ^a   Hinkson, Izumi V ^a,b   Lucin, Kurt M ^a,g   Baeza Raja, Bernat ^c   Ryu, Jae Kyu ^c   Li, Lulin ^a,b   Farina, Sasha N ^a,b   Belichenko, Nadia P ^a   Longo, Frank M ^a   Akassoglou, Katerina ^c,d   Britschgi, Markus ^a,h   Cirrito, John R ^e   Wyss Coray, Tony ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Alkahest Inc   (United States)

^g EASTERN CONNECTICUT STATE UNIVERSITY   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; LEUKADHERIN 1; MICROGLIAL COMPLEMENT RECEPTOR 3; NOOTROPIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; CD11B ANTIGEN; LEUKADHERIN-1; THIOHYDANTOIN DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INTERSTITIAL FLUID; BRAIN LEVEL; BRAIN METABOLISM; CONTROLLED STUDY; FEMALE; HALF LIFE TIME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; MICROGLIA; MICROGLIAL CELL CULTURE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; PROTEIN SECRETION; TRANSGENIC MOUSE; ANIMAL; BRAIN; C57BL MOUSE; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BENZOATES; BRAIN; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED C57BL; MICROGLIA; PROTEOLYSIS; THIOHYDANTOINS;

EID: 85020909674     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20162011     Document Type: Article

References (66)

1. Afagh, A., B.J. Cummings, D.H. Cribbs, C.W. Cotman, and A.J. Tenner. 1996. Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138:22-32. http ://dx .doi .org/10 .1006/exnr .1996 .0043
2. Bamberger, M.E., M.E. Harris, D.R. McDonald, J. Husemann, and G.E. Landreth. 2003. A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J. Neurosci. 23:2665-2674
3. Bardehle, S., V.A. Rafalski, and K. Akassoglou. 2015. Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. Front. Cell. Neurosci. 9:354. http ://dx .doi .org/10 .3389/fncel .2015 .00354
4. Bateman, R.J., L.Y. Munsell, J.C. Morris, R. Swarm, K.E. Yarasheski, and D.M. Holtzman. 2006. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12:856-861. http ://dx .doi .org/10 .1038/nm1438
5. Castellano, J.M., J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W. Patterson, A.M. Fagan, J.C. Morris, K.G. Mawuenyega, C. Cruchaga, et al. 2011. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3:89ra57. http ://dx .doi .org/10 .1126/scitranslmed .3002156
6. Cirrito, J.R., P.C. May, M.A. O'Dell, J.W. Taylor, M. Parsadanian, J.W. Cramer, J.E. Audia, J.S. Nissen, K.R. Bales, S.M. Paul, et al. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23:8844-8853
7. Cirrito, J.R., B.M. Disabato, J.L. Restivo, D.K. Verges, W.D. Goebel, A. Sathyan, D. Hayreh, G. D'Angelo, T. Benzinger, H. Yoon, et al. 2011. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. USA. 108:14968-14973. http ://dx .doi .org/10 .1073/pnas .1107411108
8. Cramer, P.E., J.R. Cirrito, D.W. Wesson, C.Y. Lee, J.C. Karlo, A.E. Zinn, B.T. Casali, J.L. Restivo, W.D. Goebel, M.J. James, et al. 2012. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 335:1503-1506. http ://dx .doi .org/10 .1126/science .1217697
9. Czirr, E., and T. Wyss-Coray. 2012. The immunology of neurodegeneration. J. Clin. Invest. 122:1156-1163. http ://dx .doi .org/10 .1172/JCI58656
10. Daborg, J., U. Andreasson, M. Pekna, R. Lautner, E. Hanse, L. Minthon, K. Blennow, O. Hansson, and H. Zetterberg. 2012. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. J. Neural Transm. (Vienna). 119:789-797. http ://dx .doi .org/10 .1007/s00702-012-0797-8
11. Eckman, E.A., S.K. Adams, F.J. Troendle, B.A. Stodola, M.A. Kahn, A.H. Fauq, H.D. Xiao, K.E. Bernstein, and C.B. Eckman. 2006. Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelinconverting enzyme but not angiotensin-converting enzyme. J. Biol. Chem. 281:30471-30478. http ://dx .doi .org/10 .1074/jbc .M605827200
12. Ehlers, M.R. 2000. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2:289-294. http ://dx .doi .org/10 .1016/S1286-4579(00)00299-9
13. Faridi, M.H., M.M. Altintas, C. Gomez, J.C. Duque, R.I. Vazquez-Padron, and V. Gupta. 2013. Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury. Biochim. Biophys. Acta. 1830:3696-3710. http ://dx .doi .org/10 .1016/j .bbagen .2013 .02 .018
14. Frackowiak, J., H.M. Wisniewski, J. Wegiel, G.S. Merz, K. Iqbal, and K.C. Wang. 1992. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils. Acta Neuropathol. 84:225-233. http ://dx .doi .org/10 .1007/BF00227813
15. Fu, H., B. Liu, J.L. Frost, S. Hong, M. Jin, B. Ostaszewski, G.M. Shankar, I.M. Costantino, M.C. Carroll, T.N. Mayadas, and C.A. Lemere. 2012. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia. Glia. 60:993-1003. http ://dx .doi .org/10 .1002/glia .22331
16. Grathwohl, S.A., R.E. Kälin, T. Bolmont, S. Prokop, G. Winkelmann, S.A. Kaeser, J. Odenthal, R. Radde, T. Eldh, S. Gandy, et al. 2009. Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nat. Neurosci. 12:1361-1363. http ://dx .doi .org/10 .1038/nn .2432
17. Gravanis, I., and S.E. Tsirka. 2005. Tissue plasminogen activator and glial function. Glia. 49:177-183. http ://dx .doi .org/10 .1002/glia .20115
18. Guerreiro, R., A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, C. Cruchaga, C. Sassi, J.S. Kauwe, S. Younkin, et al. Alzheimer Genetic Analysis Group. 2013. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368:117-127. http ://dx .doi .org/10 .1056/NEJMoa1211851
19. Hahn, S., T. Brüning, J. Ness, E. Czirr, S. Baches, H. Gijsen, C. Korth, C.U. Pietrzik, B. Bulic, and S. Weggen. 2011. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. J. Neurochem. 116:385-395. http ://dx .doi .org/10 .1111/j .1471-4159 .2010 .07118 .x
20. Hahn-Dantona, E., N. Ramos-DeSimone, J. Sipley, H. Nagase, D.L. French, and J.P. Quigley. 1999. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann. N. Y. Acad. Sci. 878:372-387. http ://dx .doi .org/10 .1111/j .1749-6632 .1999 .tb07696 .x
21. Hardy, J., and D.J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353-356. http ://dx .doi .org/10 .1126/science .1072994
22. Hernandez-Guillamon, M., S. Mawhirt, S. Fossati, S. Blais, M. Pares, A. Penalba, M. Boada, P.O. Couraud, T.A. Neubert, J. Montaner, et al. 2010. Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-β E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. J. Biol. Chem. 285:27144-27158. http ://dx .doi .org/10 .1074/jbc .M110 .135228
23. Hong, S., V.F. Beja-Glasser, B.M. Nfonoyim, A. Frouin, S. Li, S. Ramakrishnan, K.M. Merry, Q. Shi, A. Rosenthal, B.A. Barres, et al. 2016. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 352:712-716. http ://dx .doi .org/10 .1126/science .aad8373
24. Ivashkiv, L.B. 2009. Cross-regulation of signaling by ITAM-associated receptors. Nat. Immunol. 10:340-347. http ://dx .doi .org/10 .1038/ni .1706
25. Iwata, N., S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N.P. Gerard, C. Gerard, E. Hama, H.J. Lee, and T.C. Saido. 2001. Metabolic regulation of brain Aβ by neprilysin. Science. 292:1550-1552. http ://dx .doi .org/10 .1126/science .1059946
26. Jagarapu, J., J. Kelchtermans, M. Rong, S. Chen, D. Hehre, S. Hummler, M.H. Faridi, V. Gupta, and S. Wu. 2015. Efficacy of leukadherin-1 in the prevention of hyperoxia-induced lung injury in neonatal rats. Am. J. Respir. Cell Mol. Biol. 53:793-801. http ://dx .doi .org/10 .1165/rcmb .2014-0422OC
27. Jankowsky, J.L., D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, N.G. Copeland, M.K. Lee, L.H. Younkin, S.L. Wagner, et al. 2004. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum. Mol. Genet. 13:159-170. http ://dx .doi .org/10 .1093/hmg/ddh019
28. Jonsson, T., H. Stefansson, S. Steinberg, I. Jonsdottir, P.V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A.I. Levey, J.J. Lah, et al. 2013. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368:107-116. http ://dx .doi .org/10 .1056/NEJMoa1211103
29. Jun, G., A.C. Naj, G.W. Beecham, L.S. Wang, J. Buros, P.J. Gallins, J.D. Buxbaum, N. Ertekin-Taner, M.D. Fallin, R. Friedland, et al. Alzheimer's Disease Genetics Consortium. 2010. Meta-analysis confirms CR1, CLU, and PIC ALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 67:1473-1484. http ://dx .doi .org/10 .1001/archneurol .2010 .201
30. Koenigsknecht-Talboo, J., and G.E. Landreth. 2005. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25:8240-8249. http ://dx .doi .org/10 .1523/JNE URO SCI .1808-05 .2005
31. Kraft, A.W., X. Hu, H. Yoon, P. Yan, Q. Xiao, Y. Wang, S.C. Gil, J. Brown, U. Wilhelmsson, J.L. Restivo, et al. 2013. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FAS EB J. 27:187-198. http ://dx .doi .org/10 .1096/fj .12-208660
32. Lambert, J.C., S. Heath, G. Even, D. Campion, K. Sleegers, M. Hiltunen, O. Combarros, D. Zelenika, M.J. Bullido, B. Tavernier, et al. European Alzheimer's Disease Initiative Investigators. 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41:1094-1099. http ://dx .doi .org/10 .1038/ng .439
33. Linnartz, B., and H. Neumann. 2013. Microglial activatory (immunoreceptor tyrosine-based activation motif)-and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx. Glia. 61:37-46. http ://dx .doi .org/10 .1002/glia .22359
34. Lucin, K.M., and T. Wyss-Coray. 2009. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 64:110-122. http ://dx .doi .org/10 .1016/j .neuron .2009 .08 .039
35. Maier, M., Y. Peng, L. Jiang, T.J. Seabrook, M.C. Carroll, and C.A. Lemere. 2008. Complement C3 deficiency leads to accelerated amyloid β plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28:6333-6341. http ://dx .doi .org/10 .1523/JNE URO SCI .0829-08 .2008
36. Maiguel, D., M.H. Faridi, C. Wei, Y. Kuwano, K.M. Balla, D. Hernandez, C.J. Barth, G. Lugo, M. Donnelly, A. Nayer, et al. 2011. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci. Signal. 4:ra57. http ://dx .doi .org/10 .1126/scisignal .2001811
37. Mandrekar, S., Q. Jiang, C.Y. Lee, J. Koenigsknecht-Talboo, D.M. Holtzman, and G.E. Landreth. 2009. Microglia mediate the clearance of soluble Aβ through fluid phase macropinocytosis. J. Neurosci. 29:4252-4262. http ://dx .doi .org/10 .1523/JNE URO SCI .5572-08 .2009
38. Melchor, J.P., R. Pawlak, and S. Strickland. 2003. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits Aβ-induced neurodegeneration. J. Neurosci. 23:8867-8871
39. Meyer-Luehmann, M., T.L. Spires-Jones, C. Prada, M. Garcia-Alloza, A. de Calignon, A. Rozkalne, J. Koenigsknecht-Talboo, D.M. Holtzman, B.J. Bacskai, and B.T. Hyman. 2008. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature. 451:720-724. http ://dx .doi .org/10 .1038/nature06616
40. Naj, A.C., G. Jun, G.W. Beecham, L.S. Wang, B.N. Vardarajan, J. Buros, P.J. Gallins, J.D. Buxbaum, G.P. Jarvik, P.K. Crane, et al. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43:436-441. http ://dx .doi .org/10 .1038/ng .801
41. Qiu, W.Q., Z. Ye, D. Kholodenko, P. Seubert, and D.J. Selkoe. 1997. Degradation of amyloid β-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272:6641-6646. http ://dx .doi .org/10 .1074/jbc .272 .10 .6641
42. Ramos-DeSimone, N., E. Hahn-Dantona, J. Sipley, H. Nagase, D.L. French, and J.P. Quigley. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274:13066-13076. http ://dx .doi .org/10 .1074/jbc .274 .19 .13066
43. Ray, S., M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, K. Blennow, L.F. Friedman, D.R. Galasko, M. Jutel, A. Karydas, et al. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13:1359-1362. http ://dx .doi .org/10 .1038/nm1653
44. Reed, J.H., M. Jain, K. Lee, E.R. Kandimalla, M.H. Faridi, J.P. Buyon, V. Gupta, and R.M. Clancy. 2013. Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J. Biol. Chem. 288:9077-9083. http ://dx .doi .org/10 .1074/jbc .M112 .403303
45. Roberts, A.L., B.G. Fürnrohr, T.J. Vyse, and B. Rhodes. 2016. The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling. Clin. Exp. Immunol. 185:361-371. http ://dx .doi .org/10 .1111/cei .12803
46. Roberts, K.F., D.L. Elbert, T.P. Kasten, B.W. Patterson, W.C. Sigurdson, R.E. Connors, V. Ovod, L.Y. Munsell, K.G. Mawuenyega, M.M. Miller-Thomas, et al. 2014. Amyloid-β efflux from the central nervous system into the plasma. Ann. Neurol. 76:837-844. http ://dx .doi .org/10 .1002/ana .24270
47. Rockenstein, E., M. Mallory, M. Mante, A. Sisk, and E. Masliaha. 2001. Early formation of mature amyloid-β protein deposits in a mutant APP transgenic model depends on levels of Aβ1-42. J. Neurosci. Res. 66:573-582. http ://dx .doi .org/10 .1002/jnr .1247
48. Ryu, J.K., and J.G. McLarnon. 2009. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell. Mol. Med. 13:2911-2925. http ://dx .doi .org/10 .1111/j .1582-4934 .2008 .00434 .x
49. Sachs, B.D., G.S. Baillie, J.R. McCall, M.A. Passino, C. Schachtrup, D.A. Wallace, A.J. Dunlop, K.F. MacKenzie, E. Klussmann, M.J. Lynch, et al. 2007. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J. Cell Biol. 177:1119-1132. http ://dx .doi .org/10 .1083/jcb .200701040
50. Saijo, K., and C.K. Glass. 2011. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 11:775-787. http ://dx .doi .org/10 .1038/nri3086
51. Savonenko, A., G.M. Xu, T. Melnikova, J.L. Morton, V. Gonzales, M.P. Wong, D.L. Price, F. Tang, A.L. Markowska, and D.R. Borchelt. 2005. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18:602-617. http ://dx .doi .org/10 .1016/j .nbd .2004 .10 .022
52. Schafer, D.P., E.K. Lehrman, A.G. Kautzman, R. Koyama, A.R. Mardinly, R. Yamasaki, R.M. Ransohoff, M.E. Greenberg, B.A. Barres, and B. Stevens. 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 74:691-705. http ://dx .doi .org/10 .1016/j .neuron .2012 .03 .026
53. Shen, Y., L. Lue, L. Yang, A. Roher, Y. Kuo, R. Strohmeyer, W.J. Goux, V. Lee, G.V. Johnson, S.D. Webster, et al. 2001. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305:165-168. http ://dx .doi .org/10 .1016/S0304-3940(01)01842-0
54. Sisodia, S.S., E.H. Koo, P.N. Hoffman, G. Perry, and D.L. Price. 1993. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J. Neurosci. 13:3136-3142
55. Song, E.S., and L.B. Hersh. 2005. Insulysin: an allosteric enzyme as a target for Alzheimer's disease. J. Mol. Neurosci. 25:201-206. http ://dx .doi .org/10 .1385/JMN :25 :3 :201
56. Soriano, S.G., A. Coxon, Y.F. Wang, M.P. Frosch, S.A. Lipton, P.R. Hickey, and T.N. Mayadas. 1999. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke. 30:134-139. http ://dx .doi .org/10 .1161/01 .STR .30 .1 .134
57. Stevens, B., N.J. Allen, L.E. Vazquez, G.R. Howell, K.S. Christopherson, N. Nouri, K.D. Micheva, A.K. Mehalow, A.D. Huberman, B. Stafford, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell. 131:1164-1178. http ://dx .doi .org/10 .1016/j .cell .2007 .10 .036
58. Su, E.J., L. Fredriksson, M. Geyer, E. Folestad, J. Cale, J. Andrae, Y. Gao, K. Pietras, K. Mann, M. Yepes, et al. 2008. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 14:731-737. http ://dx .doi .org/10 .1038/nm1787
59. Tsirka, S.E., A. Gualandris, D.G. Amaral, and S. Strickland. 1995. Excitotoxininduced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature. 377:340-344. http ://dx .doi .org/10 .1038/377340a0
60. van Oijen, M., J.C. Witteman, A. Hofman, P.J. Koudstaal, and M.M. Breteler. 2005. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke. 36:2637-2641. http ://dx .doi .org/10 .1161/01 .STR .0000189721 .31432 .26
61. Weggen, S., J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, V. Ozols, A. Fauq, T.E. Golde, and E.H. Koo. 2003. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity. J. Biol. Chem. 278:31831-31837. http ://dx .doi .org/10 .1074/jbc .M303592200
62. Wyss-Coray, T., F. Yan, A.H. Lin, J.D. Lambris, J.J. Alexander, R.J. Quigg, and E. Masliah. 2002. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. USA. 99:10837-10842. http ://dx .doi .org/10 .1073/pnas .162350199
63. Xu, G., H. Zhang, S. Zhang, X. Fan, and X. Liu. 2008. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int. J. Clin. Pract. 62:1070-1075. http ://dx .doi .org/10 .1111/j .1742-1241 .2007 .01268 .x
64. Yan, P., X. Hu, H. Song, K. Yin, R.J. Bateman, J.R. Cirrito, Q. Xiao, F.F. Hsu, J.W. Turk, J. Xu, et al. 2006. Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281:24566-24574. http ://dx .doi .org/10 .1074/jbc .M602440200
65. Yan, P., A.W. Bero, J.R. Cirrito, Q. Xiao, X. Hu, Y. Wang, E. Gonzales, D.M. Holtzman, and J.M. Lee. 2009. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci. 29:10706-10714. http ://dx .doi .org/10 .1523/JNE URO SCI .2637-09 .2009
66. Yasojima, K., C. Schwab, E.G. McGeer, and P.L. McGeer. 1999. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154:927-936. http ://dx .doi .org/10 .1016/S0002-9440(10)65340-0